This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Betts, J. C.
Right arrow Articles by Duncan, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betts, J. C.
Right arrow Articles by Duncan, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2003, p. 2903-2913, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.2903-2913.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Signature Gene Expression Profiles Discriminate between Isoniazid-, Thiolactomycin-, and Triclosan-Treated Mycobacterium tuberculosis

Joanna C. Betts,* Alistair McLaren, Mark G. Lennon, Fiona M. Kelly, Pauline T. Lukey, Steve J. Blakemore, and Ken Duncan

GlaxoSmithKline Research and Development, Stevenage, Hertfordshire, SG1 2NY, United Kingdom

Received 10 March 2003/ Returned for modification 14 May 2003/ Accepted 23 June 2003

Genomic technologies have the potential to greatly increase the efficiency of the drug development process. As part of our tuberculosis drug discovery program, we used DNA microarray technology to profile drug-induced effects in Mycobacterium tuberculosis. Expression profiles of M. tuberculosis treated with compounds that inhibit key metabolic pathways are required as references for the assessment of novel antimycobacterial agents. We have studied the response of M. tuberculosis to treatment with the mycolic acid biosynthesis inhibitors isoniazid, thiolactomycin, and triclosan. Thiolactomycin targets the ß-ketoacyl-acyl carrier protein (ACP) synthases KasA and KasB, while triclosan inhibits the enoyl-ACP reductase InhA. However, controversy surrounds the precise mode of action of isoniazid, with both InhA and KasA having been proposed as the primary target. We have shown that although the global response profiles of isoniazid and thiolactomycin are more closely related to each other than to that of triclosan, there are differences that distinguish the mode of action of these two drugs. In addition, we have identified two groups of genes, possibly forming efflux and detoxification systems, through which M. tuberculosis may limit the effects of triclosan. We have developed a mathematical model, based on the expression of 21 genes, which is able to perfectly discriminate between isoniazid-, thiolactomycin-, or triclosan-treated M. tuberculosis. This model is likely to prove invaluable as a tool to improve the efficiency of our drug development programs by providing a means to rapidly confirm the mode of action of thiolactomycin analogues or novel InhA inhibitors as well as helping to translate enzyme activity into whole-cell activity.

* Corresponding author. Mailing address: GlaxoSmithKline Research and Development, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom. Phone: (44) 1438 768109. Fax: (44) 1438 764799. E-mail: joanna.c.betts{at}gsk.com.

Antimicrobial Agents and Chemotherapy, September 2003, p. 2903-2913, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.2903-2913.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Miller, M. B., Tang, Y.-W. (2009). Basic Concepts of Microarrays and Potential Applications in Clinical Microbiology. Clin. Microbiol. Rev. 22: 611-633 [Abstract] [Full Text]  
  • Kizer, L., Pitera, D. J., Pfleger, B. F., Keasling, J. D. (2008). Application of Functional Genomics to Pathway Optimization for Increased Isoprenoid Production. Appl. Environ. Microbiol. 74: 3229-3241 [Abstract] [Full Text]  
  • Karakousis, P. C., Williams, E. P., Bishai, W. R. (2008). Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother 61: 323-331 [Abstract] [Full Text]  
  • Parish, T., Roberts, G., Laval, F., Schaeffer, M., Daffe, M., Duncan, K. (2007). Functional Complementation of the Essential Gene fabG1 of Mycobacterium tuberculosis by Mycobacterium smegmatis fabG but Not Escherichia coli fabG. J. Bacteriol. 189: 3721-3728 [Abstract] [Full Text]  
  • Rogers, P. D., Liu, T. T., Barker, K. S., Hilliard, G. M., English, B. K., Thornton, J., Swiatlo, E., McDaniel, L. S. (2007). Gene expression profiling of the response of Streptococcus pneumoniae to penicillin. J Antimicrob Chemother 59: 616-626 [Abstract] [Full Text]  
  • Van La, M., Barbry, P., Raoult, D., Renesto, P. (2007). Molecular basis of Tropheryma whipplei doxycycline susceptibility examined by transcriptional profiling. J Antimicrob Chemother 59: 370-377 [Abstract] [Full Text]  
  • Slayden, R. A., Knudson, D. L., Belisle, J. T. (2006). Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis. Microbiology 152: 1789-1797 [Abstract] [Full Text]  
  • Bhatt, A., Kremer, L., Dai, A. Z., Sacchettini, J. C., Jacobs, W. R. Jr (2005). Conditional Depletion of KasA, a Key Enzyme of Mycolic Acid Biosynthesis, Leads to Mycobacterial Cell Lysis. J. Bacteriol. 187: 7596-7606 [Abstract] [Full Text]  
  • Poole, K. (2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51 [Abstract] [Full Text]  
  • Lin, J. T., Connelly, M. B., Amolo, C., Otani, S., Yaver, D. S. (2005). Global Transcriptional Response of Bacillus subtilis to Treatment with Subinhibitory Concentrations of Antibiotics That Inhibit Protein Synthesis. Antimicrob. Agents Chemother. 49: 1915-1926 [Abstract] [Full Text]  
  • Freiberg, C., Fischer, H. P., Brunner, N. A. (2005). Discovering the Mechanism of Action of Novel Antibacterial Agents through Transcriptional Profiling of Conditional Mutants. Antimicrob. Agents Chemother. 49: 749-759 [Abstract] [Full Text]  
  • Boshoff, H. I. M., Myers, T. G., Copp, B. R., McNeil, M. R., Wilson, M. A., Barry, C. E. III (2004). The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism: NOVEL INSIGHTS INTO DRUG MECHANISMS OF ACTION. J. Biol. Chem. 279: 40174-40184 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»